242 related articles for article (PubMed ID: 27291635)
1. Pulmonary sarcoid-like granulomatosis induced by nivolumab.
Montaudié H; Pradelli J; Passeron T; Lacour JP; Leroy S
Br J Dermatol; 2017 Apr; 176(4):1060-1063. PubMed ID: 27291635
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
Danlos FX; Pagès C; Baroudjian B; Vercellino L; Battistella M; Mimoun M; Jebali M; Bagot M; Tazi A; Lebbé C
Chest; 2016 May; 149(5):e133-6. PubMed ID: 27157227
[TBL] [Abstract][Full Text] [Related]
3. Sarcoid-like reaction and vitiligo occurring after nivolumab therapy in a patient with metastatic melanoma.
Fukuchi K; Hikawa M; Sano Y; Kasuya A; Aoshima M; Tatsuno K; Nakamura Y; Kosugi I; Tokura Y
J Dermatol; 2019 Oct; 46(10):e359-e360. PubMed ID: 30985014
[No Abstract] [Full Text] [Related]
4. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-Associated Pulmonary and Bone Sarcoidosis in a Patient With Melanoma of Unknown Primary.
Tulbah RI; Rowe SP; Solnes LB; Javadi MS
Clin Nucl Med; 2019 Sep; 44(9):e519-e521. PubMed ID: 31348077
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab in melanoma.
Specenier P
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
[TBL] [Abstract][Full Text] [Related]
7. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
8. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D
Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
[TBL] [Abstract][Full Text] [Related]
9. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab.
Gauci ML; Baroudjian B; Laly P; Madelaine I; Da Meda L; Vercellino L; Bagot M; Lioté F; Pages C; Lebbé C
Semin Arthritis Rheum; 2017 Oct; 47(2):281-287. PubMed ID: 28438383
[TBL] [Abstract][Full Text] [Related]
10. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-induced organizing pneumonia in a melanoma patient.
Sano T; Uhara H; Mikoshiba Y; Kobayashi A; Uchiyama R; Tateishi K; Yamamoto H; Okuyama R
Jpn J Clin Oncol; 2016 Mar; 46(3):270-2. PubMed ID: 26759348
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab: Immunotherapy in Malignant Melanoma.
Bayless H; Schneider S
Clin J Oncol Nurs; 2015 Aug; 19(4):430-2. PubMed ID: 26207707
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report.
Edmondson LA; Smith LV; Mallik A
J Oncol Pharm Pract; 2017 Dec; 23(8):629-634. PubMed ID: 27609337
[TBL] [Abstract][Full Text] [Related]
14. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
15. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient.
Kanno H; Ishida K; Yamada W; Nishida T; Takahashi N; Mochizuki K; Mizuno Y; Matsuyama K; Takahashi T; Seishima M
J Infect Chemother; 2017 Nov; 23(11):774-777. PubMed ID: 28527652
[TBL] [Abstract][Full Text] [Related]
16. Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report.
Harada M; Naoi H; Yasuda K; Ito Y; Kagoo N; Kubota T; Ichijo K; Mochizuki E; Uehara M; Matsuura S; Tsukui M; Koshimizu N
BMC Pulm Med; 2021 Jan; 21(1):6. PubMed ID: 33407304
[TBL] [Abstract][Full Text] [Related]
17. Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report.
Ozaki Y; Shindoh J; Miura Y; Nakajima H; Oki R; Uchiyama M; Masuda J; Kinowaki K; Kondoh C; Tanabe Y; Tanaka T; Haruta S; Ueno M; Kitano S; Fujii T; Udagawa H; Takano T
BMC Cancer; 2017 Nov; 17(1):778. PubMed ID: 29162045
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
19. Case 286: Sarcoidlike Granulomatosis and Lymphadenopathy-Thoracic Manifestations of Nivolumab Drug Toxicity.
Chiang J; Hebroni F; Bedayat A; Pourzand L
Radiology; 2021 Feb; 298(2):471-475. PubMed ID: 33493088
[TBL] [Abstract][Full Text] [Related]
20. Bilateral uveitis and macular edema induced by Nivolumab: a case report.
Theillac C; Straub M; Breton AL; Thomas L; Dalle S
BMC Ophthalmol; 2017 Dec; 17(1):227. PubMed ID: 29195497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
